We knew it was coming,...should provide good support as long as the good news promotion keeps coming. CDN$75+ million added to the balance sheet will double what's there already. Strike while the iron's hot!
Vasogen Announces Offering of Common Shares
MISSISSAUGA, ON, Feb. 9 /CNW/ - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), a
developer of immune modulation therapies for the treatment of cardiovascular
disease and other chronic inflammatory disorders, today announced that it is
commencing a public offering of 8 million common shares in the United States
and Canada. Needham & Company, Inc. and RBC Capital Markets are lead managers
for the offering, with A.G. Edwards & Sons, Inc. acting as a co-manager. This
offering is being made by way of a preliminary prospectus supplement filed in
the United States and all Canadian provinces and territories and pursuant to
Vasogen's currently effective short form base shelf prospectus, which has been
filed on Form F-10 for the offering of common shares with the United States
Securities and Exchange Commission.
The company intends to grant the underwriters an option for 30 days to
purchase up to an additional 1,200,000 common shares to cover over-allotments,
if any.
Vasogen intends to use the proceeds from the proposed offering to advance
the research and commercial development of Celacade(TM) (immune modulation
therapy), to further fund its new drug development pipeline, including VP025,
and for general corporate purposes.
When available, copies of the preliminary prospectus supplement and base
shelf prospectus relating to the offering may be obtained from the
underwriters at:
Needham & Company, Inc. RBC Capital Markets
445 Park Avenue 200 Bay Street, Royal Bank Plaza
New York, NY 10022 Toronto, ON M5J 2W7
Telephone 212-371-8300 Telephone 416-842-2000
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of the common
shares in any state in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
such state.
Vasogen Files Shelf Prospectus
MISSISSAUGA, ON, Oct. 20 /CNW/ - Vasogen Inc. (TSX:VAS; AMEX:VSV) today
announced that it has filed a preliminary short form shelf prospectus with the
securities regulatory authorities in the provinces of Canada and a
corresponding registration statement with the United States Securities and
Exchange Commission on Form F-10. Once the prospectus is cleared and the shelf
registration statement becomes effective, these filings would provide for the
potential offering of up to an aggregate of US$100 million of the Company's
common shares from time to time in one or more offerings. The terms of any
such future offerings would be established at the time of such offering. At
the time any of the shares covered by the shelf prospectus are offered for
sale, a prospectus supplement containing specific information about the terms
of any such offering will be provided. A copy of the shelf prospectus may be
obtained from Glenn Neumann, Director of Investor Relations.
A registration statement relating to these securities has been filed with
the United States Securities and Exchange Commission, but has not yet become
effective. These securities may not be sold, nor may offers to buy be accepted
prior to the time the registration statement becomes effective. This press
release shall not constitute an offer to sell or the solicitation of an offer
to buy, nor shall there be any sale of these securities in any state in which
such offer, solicitation, or sale would be unlawful prior to the registration
or qualification under the securities laws of any such state. |
